Atieh Karimzadeh: Romiplostim Shows High Response and Reduced Bleeding in Pediatric HSCT
Atieh Karimzadeh, Postdoctoral Research Fellow at the Pediatric Cell and Gene Therapy Research Center, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Transplantation and Cellular Therapy, adding:
“Excited to share another publication from our team!
Our study, ‘Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients‘, has been published in the Transplantation and Cellular Therapy (Q1, IF=4.4)
In the largest prospective pediatric study to date on this topic, we found that romiplostim achieved an impressive 80.9% response rate, significantly reduced bleeding events, and
helped most patients become transfusion-independent – all with an excellent safety profile.
These findings highlight the potential of romiplostim as an effective supportive care strategy for children experiencing prolonged thrombocytopenia after HSCT.
Special thanks to Amir Ali Hamidieh and Maryam Behfar for their invaluable mentorship, guidance, and support throughout this project.
Shout out to the brilliant Zahra Karimizadeh for this amazing collaboration.
Proud to contribute to advancing pediatric HSCT research and improving patient outcomes.”
Title: Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial
Authors: Zahra Karimizadeh, Maryam Behfar, Atieh Karimzadeh, Leila Jafari, Amirali Kalantari, Zeynab Nikfetrat, Amir Ali Hamidieh
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 20, 2026, 08:58Samantha Pasca: Insights into Pain and Coping in Hemophilia at ISTH 2026
-
Jul 20, 2026, 08:08Ifeanyichukwu Ifechidere: COVID-19 Changed Our Understanding of Coagulation
-
Jul 20, 2026, 07:27Vonwicks Czelestakov Onyango: The Anticoagulation Dilemma in Ulcerative Colitis
-
Jul 20, 2026, 06:14Elen Avetisyan: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same
-
Jul 19, 2026, 16:58Axel Cangas: Exploring the Future of Hemophilia Care at ISTH 2026
-
Jul 19, 2026, 16:58Aviva Schwartz: Air Pollution and Women’s Hematological Health in the Spotlight at ISTH 2026
-
Jul 19, 2026, 16:56Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
-
Jul 19, 2026, 16:54Belén de la Morena Barrio: Presenting Our Research on Long-Read Sequencing for Genetic Diagnosis at ISTH 2026